Abstract
The use of aspirin and clopidogrel in combination has become part of the standard clinical care of patients with coronary artery disease. The use of this combination provides significant benefits compared with the use of aspirin alone in patients with acute coronary syndromes, and in patients treated with percutaneous coronary intervention with stent placement (both bare metal and drug-eluting stents). Clinical trials have demonstrated significant efficacy of this dual therapy; however, there is the potential for significant bleeding complications from the synergistic antiplatelet effects. In total, it appears that when there is vessel injury (mechanical from perctutaneous coronary intervention or a ruptured plaque), dual antiplatelet therapy with aspirin and clopidogrel results in improved outcomes, albeit with a small but significant inherent risk of increased bleeding.
| Original language | English |
|---|---|
| Pages (from-to) | 815-826 |
| Number of pages | 12 |
| Journal | Expert Opinion on Drug Safety |
| Volume | 5 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 1 2006 |
Fingerprint
Keywords
- Aspirin
- Atherothrombosis
- Blood platelet
- Clopidogrel
- Coronary artery disease
ASJC Scopus subject areas
- Pharmacology
Cite this
The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. / Coole, Glen E.; Goldschmidt-Clermont, Pascal.
In: Expert Opinion on Drug Safety, Vol. 5, No. 6, 01.11.2006, p. 815-826.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease
AU - Coole, Glen E.
AU - Goldschmidt-Clermont, Pascal
PY - 2006/11/1
Y1 - 2006/11/1
N2 - The use of aspirin and clopidogrel in combination has become part of the standard clinical care of patients with coronary artery disease. The use of this combination provides significant benefits compared with the use of aspirin alone in patients with acute coronary syndromes, and in patients treated with percutaneous coronary intervention with stent placement (both bare metal and drug-eluting stents). Clinical trials have demonstrated significant efficacy of this dual therapy; however, there is the potential for significant bleeding complications from the synergistic antiplatelet effects. In total, it appears that when there is vessel injury (mechanical from perctutaneous coronary intervention or a ruptured plaque), dual antiplatelet therapy with aspirin and clopidogrel results in improved outcomes, albeit with a small but significant inherent risk of increased bleeding.
AB - The use of aspirin and clopidogrel in combination has become part of the standard clinical care of patients with coronary artery disease. The use of this combination provides significant benefits compared with the use of aspirin alone in patients with acute coronary syndromes, and in patients treated with percutaneous coronary intervention with stent placement (both bare metal and drug-eluting stents). Clinical trials have demonstrated significant efficacy of this dual therapy; however, there is the potential for significant bleeding complications from the synergistic antiplatelet effects. In total, it appears that when there is vessel injury (mechanical from perctutaneous coronary intervention or a ruptured plaque), dual antiplatelet therapy with aspirin and clopidogrel results in improved outcomes, albeit with a small but significant inherent risk of increased bleeding.
KW - Aspirin
KW - Atherothrombosis
KW - Blood platelet
KW - Clopidogrel
KW - Coronary artery disease
UR - http://www.scopus.com/inward/record.url?scp=33750555770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750555770&partnerID=8YFLogxK
U2 - 10.1517/14740338.5.6.815
DO - 10.1517/14740338.5.6.815
M3 - Article
VL - 5
SP - 815
EP - 826
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 6
ER -